The RB Tumor Suppressor Positively Regulates Transcription of the Anti-angiogenic Protein NOL7

The expression of the angiogenic phenotype is regulated by a balance of pro-angiogenic and anti-angiogenic factors released into the tumor microenvironment. Nuclear protein 7 (NOL7), a novel tumor suppressor, acts as a master regulator of angiogenesis by downregulating pro-angiogenic factors and up...

Full description

Bibliographic Details
Main Authors: Tanmayi P. Mankame, Mark W. Lingen
Format: Article
Language:English
Published: Elsevier 2012-12-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558612800571
id doaj-85abe1e4b64045319fd1fe87baedbc1c
record_format Article
spelling doaj-85abe1e4b64045319fd1fe87baedbc1c2020-11-24T23:04:53ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022012-12-0114121213122210.1593/neo.121422The RB Tumor Suppressor Positively Regulates Transcription of the Anti-angiogenic Protein NOL7Tanmayi P. MankameMark W. Lingen The expression of the angiogenic phenotype is regulated by a balance of pro-angiogenic and anti-angiogenic factors released into the tumor microenvironment. Nuclear protein 7 (NOL7), a novel tumor suppressor, acts as a master regulator of angiogenesis by downregulating pro-angiogenic factors and upregulating anti-angiogenic factors. Using cervical cancer as a model of investigation, we have previously shown that loss of NOL7 mRNA and protein expression is observed as early as the premalignant phase. Analysis of the gene failed to identify tumor-specific promoter methylation or coding region mutations, suggesting that NOL7 loss may be mediated by aberrant expression of its upstream regulators. In this study, we show that the RB tumor suppressor gene (RB) positively regulates NOL7 at the transcriptional level by recruiting transcription factors and transcription machinery proteins to its promoter region. Conversely, the loss of RB represses NOL7 transcription by inhibiting assembly of these proteins. This loss of NOL7 expression is also observed in RB-deficient human malignancies. Together, this work further characterizes the transcriptional activator function of RB and defines a potential role for RB in regulating angiogenesis through activation of NOL7. Current anti-angiogenic therapies lack long-term efficacy, as they are unable to target the diverse angiogenic signals generated by tumors. Our data provide evidence to support the hypothesis that reactivation of pRB can potentially modulate the expression of the angiogenic phenotype through regulation of NOL7. Therefore, this knowledge may be employed to design more comprehensive and effective therapies. http://www.sciencedirect.com/science/article/pii/S1476558612800571
collection DOAJ
language English
format Article
sources DOAJ
author Tanmayi P. Mankame
Mark W. Lingen
spellingShingle Tanmayi P. Mankame
Mark W. Lingen
The RB Tumor Suppressor Positively Regulates Transcription of the Anti-angiogenic Protein NOL7
Neoplasia: An International Journal for Oncology Research
author_facet Tanmayi P. Mankame
Mark W. Lingen
author_sort Tanmayi P. Mankame
title The RB Tumor Suppressor Positively Regulates Transcription of the Anti-angiogenic Protein NOL7
title_short The RB Tumor Suppressor Positively Regulates Transcription of the Anti-angiogenic Protein NOL7
title_full The RB Tumor Suppressor Positively Regulates Transcription of the Anti-angiogenic Protein NOL7
title_fullStr The RB Tumor Suppressor Positively Regulates Transcription of the Anti-angiogenic Protein NOL7
title_full_unstemmed The RB Tumor Suppressor Positively Regulates Transcription of the Anti-angiogenic Protein NOL7
title_sort rb tumor suppressor positively regulates transcription of the anti-angiogenic protein nol7
publisher Elsevier
series Neoplasia: An International Journal for Oncology Research
issn 1476-5586
1522-8002
publishDate 2012-12-01
description The expression of the angiogenic phenotype is regulated by a balance of pro-angiogenic and anti-angiogenic factors released into the tumor microenvironment. Nuclear protein 7 (NOL7), a novel tumor suppressor, acts as a master regulator of angiogenesis by downregulating pro-angiogenic factors and upregulating anti-angiogenic factors. Using cervical cancer as a model of investigation, we have previously shown that loss of NOL7 mRNA and protein expression is observed as early as the premalignant phase. Analysis of the gene failed to identify tumor-specific promoter methylation or coding region mutations, suggesting that NOL7 loss may be mediated by aberrant expression of its upstream regulators. In this study, we show that the RB tumor suppressor gene (RB) positively regulates NOL7 at the transcriptional level by recruiting transcription factors and transcription machinery proteins to its promoter region. Conversely, the loss of RB represses NOL7 transcription by inhibiting assembly of these proteins. This loss of NOL7 expression is also observed in RB-deficient human malignancies. Together, this work further characterizes the transcriptional activator function of RB and defines a potential role for RB in regulating angiogenesis through activation of NOL7. Current anti-angiogenic therapies lack long-term efficacy, as they are unable to target the diverse angiogenic signals generated by tumors. Our data provide evidence to support the hypothesis that reactivation of pRB can potentially modulate the expression of the angiogenic phenotype through regulation of NOL7. Therefore, this knowledge may be employed to design more comprehensive and effective therapies.
url http://www.sciencedirect.com/science/article/pii/S1476558612800571
work_keys_str_mv AT tanmayipmankame therbtumorsuppressorpositivelyregulatestranscriptionoftheantiangiogenicproteinnol7
AT markwlingen therbtumorsuppressorpositivelyregulatestranscriptionoftheantiangiogenicproteinnol7
AT tanmayipmankame rbtumorsuppressorpositivelyregulatestranscriptionoftheantiangiogenicproteinnol7
AT markwlingen rbtumorsuppressorpositivelyregulatestranscriptionoftheantiangiogenicproteinnol7
_version_ 1725628797006381056